21Sep 2024
Dupilumab and Ocular Events in Atopic Dermatitis

Dupilumab and Ocular Events in Atopic Dermatitis

The study explores ocular adverse events (OAE) in atopic dermatitis (AD) patients treated with dupilumab. Researchers analyzed conjunctival cells from 36 patients before (M0) and 4 months after (M4) treatment, categorizing them into those with OAE (OAE+) and without (OAE-). At M0, 52 differentially expressed genes (DEGs) were identified, increasing to 113 at M4. OAE+ patients exhibited a psoriasis signature and upregulated genes linked to keratinocyte differentiation. Validation confirmed 9 DEGs, suggesting that certain transcriptomic profiles may predispose AD patients to develop OAE during dupilumab treatment.

  • #dermatology

Like

Save

Share